0000950170-23-031850.txt : 20230705 0000950170-23-031850.hdr.sgml : 20230705 20230705211109 ACCESSION NUMBER: 0000950170-23-031850 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230705 DATE AS OF CHANGE: 20230705 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Freeman Roy Lester CENTRAL INDEX KEY: 0001799732 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 231071803 MAIL ADDRESS: STREET 1: 256 SUMMIT AVE CITY: BROOKLINE STATE: MA ZIP: 02446 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 4 1 ownership.xml 4 X0407 4 2023-06-30 0001750149 Inhibikase Therapeutics, Inc. IKT 0001799732 Freeman Roy Lester 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 true false false false false Stock Option (right to buy) 3.61 2023-06-30 4 A false 6667 0.00 A 2030-06-30 Common Stock 6667 6667 D The options will vest on the earlier of June 30, 2024 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. /s/ Milton H. Werner, attorney-in-fact 2023-07-05